Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL101 Prior to Surgery in Notch Activated Adenoid Cystic Carcinoma
NCT04973683Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osugacestat in adenoid cystic carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 2 years and Changes in NICD1 levels. Started Sep 2021; status: completed.
02
Drugs
osugacestat
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT04973683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973683.